

# The $\beta$ -lactamase inhibitor avibactam (NXL104) does not induce *ampC* $\beta$ -lactamase in *Enterobacter cloacae*

Christine Miossec  
Monique Claudon  
Premavathy Levasseur  
Michael T Black

Novoxel, Romainville, France

**Abstract:** Induction of *ampC*  $\beta$ -lactamase expression can often compromise antibiotic treatment and is triggered by several  $\beta$ -lactams (such as cefoxitin and imipenem) and by the  $\beta$ -lactamase inhibitor clavulanic acid. The novel  $\beta$ -lactamase inhibitor avibactam (NXL104) is a potent inhibitor of both class A and class C enzymes. The potential of avibactam for induction of *ampC* expression in *Enterobacter cloacae* was investigated by *ampC* messenger ribonucleic acid quantitation. Cefoxitin and clavulanic acid were confirmed as *ampC* inducers, whereas avibactam was found to exert no effect on *ampC* expression. Thus, avibactam is unlikely to diminish the activity of any partner  $\beta$ -lactam antibiotic against AmpC-producing organisms.

**Keywords:**  $\beta$ -lactamase, *ampC*, induction, NXL104, avibactam

## Introduction

Bacterial resistance to  $\beta$ -lactams and  $\beta$ -lactamase inhibitors is an ever-increasing problem that compromises their clinical utility. Among Gram-negative bacteria, the production of  $\beta$ -lactamases is the most frequent factor contributing to  $\beta$ -lactam resistance. Of particular concern are enzymes able to target the expanded-spectrum  $\beta$ -lactams, including the AmpC enzymes (class C cephalosporinases), the so-called extended-spectrum- $\beta$ -lactamases (ESBL; classes A and D), and the carbapenemases, which hydrolyze most  $\beta$ -lactams, including the carbapenems (classes A, B, and D).<sup>1</sup>

In order to restore their antibacterial activity against Gram-negative pathogens,  $\beta$ -lactams have been paired with inhibitors of  $\beta$ -lactamases. Those currently used in the clinical setting (clavulanate, tazobactam, and sulbactam) have a spectrum of inhibition essentially covering class A enzymes. All three marketed inhibitors contain a  $\beta$ -lactam core and share a similar mechanism of inhibition. They react with serine enzymes to form a covalent acyl-enzyme intermediate; opening of the four-member  $\beta$ -lactam ring is followed by considerable molecular rearrangement before hydrolysis to regenerate the active enzyme.<sup>2</sup>

Avibactam (NXL104) is a non- $\beta$ -lactam  $\beta$ -lactamase inhibitor that displays a broad-spectrum inhibition profile, with potent inhibition of class A, class C, and some class D enzymes. The inhibitor is characterized by high carbamylation efficiency and slow decarbamylation, resulting in a long half-life of the inactive covalent adduct.<sup>3</sup> In addition, the decarbamylation step results in regeneration of intact avibactam, and not hydrolysis.<sup>4</sup> Avibactam has little intrinsic antibacterial activity, but efficiently protects  $\beta$ -lactams from hydrolysis in a variety of class A, class C, and some class

Correspondence: Christine Miossec  
27 Rue Stendhal, Paris 75020, France  
Tel +33 6 8976 2978  
Email miossec.christine@gmail.com

D-producing strains, including ESBL, *Klebsiella pneumoniae* carbapenemase (KPC), and OXA-48 producers.<sup>5-7</sup>

Many strains of the Enterobacteriaceae family, as well as some nonfermenters, such as *Pseudomonas aeruginosa* and *Acinetobacter baumannii*, encode a chromosomal AmpC  $\beta$ -lactamase, although the regulation of enzyme production is different among the various enzyme-producing strains. In *Escherichia coli*, enzyme expression is usually constitutive and low-level, whereas in other species, such as *Enterobacter* spp., *Citrobacter freundii*, *Serratia* spp., *Morganella morganii*, *Providencia* spp., or *P. aeruginosa*, it can be transiently induced to higher levels by several  $\beta$ -lactam compounds, with carbapenems and cephamycins generally having the highest induction potential.<sup>8</sup> Derepression can also occur by mutations favoring constitutive production of very high levels of  $\beta$ -lactamase. The mechanism of induction is complex, via a system involving AmpD, AmpR, AmpG, and intermediates in peptidoglycan recycling.<sup>9</sup>

Induction of *ampC* does not necessarily correlate with a risk of clinical failure, particularly when the rate of bactericidal activity is high. However, the potential for *ampC* induction has to be carefully examined when considering administration of a  $\beta$ -lactamase inhibitor, because it can antagonize the antibacterial activity of its partner  $\beta$ -lactam.<sup>10-12</sup> Indeed, the antibacterial activity of a given  $\beta$ -lactam with limited stability to AmpC is preserved, provided that its potential for *ampC* induction is low. In contrast, its activity would be compromised if combined with a  $\beta$ -lactamase inhibitor that induces significant AmpC production.

The aim of this study was to investigate the ability of avibactam to induce *ampC* expression in *E. cloacae* strains in vitro. Because  $\beta$ -lactamase/avibactam complexes are known to have a long half-life, it was not possible to evaluate AmpC induction by measuring directly the  $\beta$ -lactamase activity produced by avibactam-treated cells. Thus, it was measured by quantitation of cellular *ampC* messenger ribonucleic acid (mRNA). Cefoxitin and clavulanate were used as reference *ampC* inducers.

## Materials and methods

### Bacterial strains and susceptibility testing

*E. cloacae* isolates used in this study were obtained from the Novaxel culture collection, originally collected from a variety of clinical or laboratory sources. Minimal inhibitory concentration (MIC) determinations were performed according to the Clinical and Laboratory Standards Institute broth-microdilution methods using cation-adjusted Mueller–Hinton broth.<sup>13</sup> MIC values were measured for cefoxitin

(Sigma-Aldrich, St Louis, MO, USA) and ceftazidime (Novartis, Basel, Switzerland); the latter was tested alone or in association with clavulanate (US Pharmacopeial Convention, Rockville, MD, USA) or avibactam, at a constant inhibitor concentration of 4 mg/L.

### Induction experiments

Bacterial strains were grown overnight at 37°C in Luria–Bertani broth (Interchim, Montlignon, France), then diluted to an optical density (OD<sub>600 nm</sub>) value of 0.1 and incubated with shaking for 2–4 hours to reach midlog-growth phase. At this point, the test inducer (cefoxitin, clavulanate, or avibactam) was added at the appropriate concentration (8, 16, 32, or 64  $\mu$ g/mL), whereas control cultures were grown in the absence of inducer. Approximately  $5 \times 10^8$  cells were sampled for RNA extraction just before addition of inducer, and at timed intervals thereafter up to 6 hours. Each induction experiment was performed at least three times for all three *E. cloacae* strains.

### Reverse-transcription polymerase chain reaction

Total cellular RNA was extracted with an RNeasy RNA Protect Mini Kit (Qiagen, Venlo, the Netherlands), and residual deoxyribonucleic acid (DNA) was eliminated by treatment with an RNase-free DNase Set (Qiagen). Analysis of RNA integrity and total RNA quantification was performed using the Agilent 2100 RNA bioanalyzer and the Nano 6000 kit (Agilent Technologies, Santa Clara, CA, USA).

Polymerase chain reaction (PCR) primers were designed with Primer Express software for *ampC* (forward 5'-TGGCGTATCGGGTCAATGT-3'; probe 5'-TCAGGGTCTGGGCTGGGAGATGC-3'; reverse 5'-CCTCCACGGGCCAGTTG-3') and for *rpsL* (forward 5'-CAGGTGACACCGTGGAAAGTG-'; probe 5'-AAGTATGGGTTGTTGAAGGTTCCAA-3'; reverse 5'-CGAATGCCTGCAGACGTTT-3'). The probe primers were modified by addition of 6-FAM (6-carboxy-fluorescein) at the 5' end and TAMRA (6-carboxy-tetramethyl-rhodamine) at the 3' end.

Real-time PCR (RT-PCR) reactions were carried out in the ABI Prism® 7000 sequence-detection system (Life Technologies, Carlsbad, CA, USA) using a Quantitect Probe RT-PCR kit (Qiagen). Individual reactions were set up in triplicate for either *ampC* or *rpsL* genes, according to the manufacturer's recommendations. Briefly, complementary DNA was synthesized from 0.5 ng of RNA using Moloney murine leukemia virus reverse transcriptase and 0.7  $\mu$ M of each primer; reverse transcription was carried out at 50°C for 30 minutes.

PCR conditions were as follows: initial activation of DNA polymerase at 95°C for 15 minutes, and PCR for 40 cycles at 95°C for 15 seconds, 60°C for 60 seconds. Absence of genomic DNA contamination was verified for each RNA preparation by running the assay in the absence of reverse transcriptase. Data were analyzed using Sequence Detection 2.0 software (Life Technologies). To correct for differences in the amount of starting material, the ribosomal *E. cloacae* *rplS* gene (encoding ribosomal protein 19) was chosen as a housekeeping reference gene. Values obtained were then normalized to that of *ampC* from *E. cloacae* strain P99 for measurement of basal expression, or to that of *ampC* in the test strain before induction. Relative quantitation was carried out by using the  $2^{-\Delta\Delta C_T}$  method, as recommended by the manufacturer.<sup>14</sup> Normalized *ampC* expression in culture 2 relative to that in culture 1 was calculated as follows:

$$\frac{\text{ampC (culture 2)}}{\text{ampC (culture 1)}} = 2^{-[(Ct \text{ ampC in culture 2} - Ct \text{ rplS in culture 2}) - (Ct \text{ ampC in culture 1} - Ct \text{ rplS in culture 1})]}$$

## $\beta$ -Lactamase activity assays

Crude bacterial extracts were prepared by vortexing bacterial cells with glass beads in 100 mM phosphate buffer pH 7 containing 0.1 mg/mL of bovine serum albumin and 2% v/v glycerol (about  $10^{11}$  bacterial cells/mL).  $\beta$ -Lactamase activity was measured using a spectrophotometer at 485 nm for 15 minutes using 180  $\mu$ L of crude cell lysate at appropriate dilution, and 20  $\mu$ L of 1 mM nitrocefin (Oxoid SR112C). Results were expressed as initial reaction rates ( $\Delta A_{485 \text{ nm}}/\text{minute}$ ) per  $10^6$  cells or per milligram of protein.

## Results

Both cefoxitin and ceftazidime are good AmpC substrates; cefoxitin is also a good *ampC* inducer, whereas ceftazidime has limited potential for induction. The differential activity

of cefoxitin and ceftazidime can therefore be used to infer the presence of an inducible *ampC* gene, as strains without significant levels of AmpC enzyme remain susceptible to cefoxitin.<sup>9,15</sup> In order to select potentially inducible strains for this study, three *E. cloacae* strains (293LA2, 293HT107, and 293UC1) were chosen on the basis of resistance to cefoxitin and susceptibility to ceftazidime. The *E. cloacae* P99 strain was included in this study as a reference, having a cefoxitin-resistant (cefoxitin-R) and ceftazidime-R phenotype (stably derepressed high-level AmpC producer). The MIC values obtained for these four strains are shown in Table 1. As expected, owing to its spectrum of coverage limited to class A enzymes, clavulanate had no effect on the high ceftazidime MIC value for the P99 strain; in contrast, avibactam reduced ceftazidime MIC to a susceptible level in this strain.

Induction of  $\beta$ -lactamases is most frequently assessed by assaying  $\beta$ -lactamase activity using spectrophotometric assays of nitrocefin hydrolysis, in the presence or absence of an inducer. However, this is not technically possible when testing the induction potential of a compound that can form highly stable complexes with AmpC enzymes (half-life around 7 days for avibactam/P99 AmpC complex).<sup>5</sup> Therefore, induction was measured by quantitation of *ampC* transcripts using RT-PCR. However,  $\beta$ -lactamase enzymatic activity was measured using nitrocefin in parallel with RT-PCR in the experiments that did not involve exposure to  $\beta$ -lactamase inhibitors. Basal expression of *ampC* mRNA in those three *E. cloacae* strains was compared to that of derepressed AmpC P99 and found to be 150- to 300-fold lower (Table 1). Concomitantly, basal  $\beta$ -lactamase activity in crude cell extracts reported using the nitrocefin substrate was also higher (1,000- to 1,800-fold) in P99 than in the three selected *E. cloacae* strains. Basal levels of *ampC* transcripts and  $\beta$ -lactamase activity were therefore fully consistent with the susceptibility/resistance phenotype of the strains.

**Table 1** Susceptibility to antibiotics, basal expression of *ampC* mRNA and  $\beta$ -lactamase activity in *Enterobacter cloacae* strains

<i>E. cloacae</i> strain	P99	293LA2	293HT107	293UC1
Phenotype	Cefoxitin-R	Cefoxitin-R	Cefoxitin-R	Cefoxitin-R
	Ceftazidime-R	Ceftazidime-S	Ceftazidime-S	Ceftazidime-S
MIC ( $\mu$ g/mL)				
Cefoxitin	>128	>128	64	128
Ceftazidime	>128	2	0.5	8
Ceftazidime + clavulanate	>128	4	2	16
Ceftazidime + avibactam	1	1	<0.12	0.25
Normalized <i>ampC</i> mRNA*	1.0000	0.0035	0.0040	0.0066
Activity against nitrocefin <sup>#</sup>	229	0.13	0.22	0.18

**Notes:** \*Values represent fold change in comparison with transcription level in P99 strain; <sup>#</sup> $\beta$ -lactamase activity is expressed as initial reaction rate ( $\Delta A_{485 \text{ nm}}/\text{minute}$ ) per  $10^6$  cells.

**Abbreviations:** MIC, minimum inhibitory concentration; mRNA, messenger ribonucleic acid.

The inducibility of  $\beta$ -lactamase activity was studied in the presence of 1–32 mg/L cefoxitin. The three *E. cloacae* strains tested showed similar induction profiles: *ampC* mRNA peaked at 1–2 hours following induction, then slowly declined to reach basal levels at 4–6 hours. Figure 1 shows the kinetics of one representative experiment with the strain 293HT107 treated with cefoxitin at 1 or 2 mg/L. Increased mRNA concentrations were detectable soon after incubation start (as soon as 10 minutes; data not shown) and peaked after 1–2 hours of incubation.  $\beta$ -Lactamase activity was delayed slightly when compared to *ampC* mRNA and continuously increased throughout the 4 hours of incubation with cefoxitin. When treated with 16–32 mg/L of cefoxitin, the maximal *ampC* transcriptional level after 2 hours of culture was between 100 and 200 times the basal level of both 293HT107 (Figure 2G) and 293LA2 (Figure 2D) strains, and around 50 times the basal level of the 293UC1 strain (Figure 2A).


The potential of avibactam and clavulanate for induction of *ampC* expression was evaluated on the three *E. cloacae* strains at 16–64 mg/L. Clavulanate had no significant effects on 293UC1 and 293LA2 strains during the 6-hour incubation period (Figure 2B and E), whereas it was a moderate *ampC* inducer for 293HT107 with about a 40-fold increase of *ampC* mRNA at 64 mg/L after 2 hours of incubation (Figure 2H). In contrast, avibactam had no detectable effect on *ampC* mRNA

levels in the three strains tested (Figure 2, C, F, and I). At the concentrations used for induction studies, avibactam had no effect on the growth of the bacterial strains tested, as testified by the OD values measured at each time point.


## Discussion

*Enterobacter* spp. are recognized to be among the most common nosocomial pathogens, with current resistance rates presenting a serious therapeutic dilemma. Resistance through overexpression of AmpC can occur in the vast majority of strains possessing a chromosomally encoded cephalosporinase, and *ampC* induction is recognized as a widespread resistance mechanism. In a study examining 200 clinical isolates of *P. aeruginosa*, *Enterobacter* spp., *Citrobacter* spp., and *Serratia* spp., it was shown that 85% of the collected strains showed inducible AmpC production, of which 11% were stably derepressed and only 3% were not induced by either cefoxitin or imipenem.<sup>16</sup> Approximately 12% of hospital strains of the European Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) program in the years 1997–2000 were due to potential AmpC-producing strains of *Enterobacter* spp., *Citrobacter* spp., and *S. marcescens*, in which 28% represented stably derepressed AmpC-producing phenotypes.<sup>17</sup>

Much of what is known about AmpC regulation is from studies in *E. coli*, *C. freundii*, and *E. cloacae*; the induction



**Figure 1** Kinetics of *ampC* transcription and  $\beta$ -lactamase activity in *Enterobacter cloacae* 293HT107. *E. cloacae* strain 293HT107 was incubated with cefoxitin at 1 mg/L (triangles), 2 mg/L (squares), or in control medium (open circles). After 0.5, 1, 2, and 4 hours of culture, *ampC* messenger ribonucleic acids (mRNA) were quantified by real-time polymerase chain reaction (continuous lines; values show fold change in comparison with transcription level before incubation), and  $\beta$ -lactamase activity was measured spectrophotometrically (dashed lines).



**Figure 2 (A–I)** Potential for *ampC* induction of cefoxitin, clavulanate, and avibactam. *Enterobacter cloacae* strains 293UC1 (A–C), 293LA2 (D–F), and 293HT107 (G–I) were incubated with cefoxitin (A, D and G), clavulanate (B, E and H), or avibactam (C, F and I). Inducers were used at various concentrations: 8 mg/L (squares), 16 mg/L (triangles), 32 mg/L (filled circles), or 64 mg/L (open circles); control cultures are shown with dashed lines. *ampC* messenger ribonucleic acids were quantified by real-time polymerase chain reaction after 2, 4, and 6 hours of culture.

mechanism in response to exposure to certain  $\beta$ -lactams is complex and closely linked to the peptidoglycan-recycling pathway.<sup>9</sup> Different effector proteins and regulation mechanisms have been recently evidenced for *P. aeruginosa ampC* induction, suggesting that the process is more complex in that species and distinct from the current paradigm established following studies of Enterobacteriaceae species.<sup>18</sup>

$\beta$ -lactams differ in their inducing abilities, with carbapenems and cephamycins having the highest potential.<sup>8</sup> The clavulanate  $\beta$ -lactamase inhibitor is also an *ampC* inducer, and was shown in vitro to antagonize the antibacterial activity of various  $\beta$ -lactams.<sup>10,11</sup> In this context, the potential for induction of the new  $\beta$ -lactamase inhibitor avibactam was evaluated. At sub-MIC concentrations, cefoxitin induced a major dose-dependent synthesis of *ampC* in all three *E. cloacae* strains tested here, whereas clavulanate triggered synthesis of *ampC* mRNA in

two out of the three strains, at the highest concentration tested (64 mg/L). In contrast, in the same range of concentrations, avibactam had no effect on cellular *ampC* mRNA concentration in any of the three *E. cloacae* strains during the 6-hour incubation period. From these initial findings, it is concluded that there is little likelihood of antagonism between  $\beta$ -lactam antibiotics and the novel  $\beta$ -lactamase inhibitor avibactam in *Enterobacter* spp. Questions remain about other bacterial species producing inducible chromosomal AmpC enzymes, and will be the focus of future studies.

Avibactam is the first compound of a diazabicyclo-octane series. In contrast with the inhibitors currently available (clavulanate, tazobactam, and sulbactam), which all have relatively limited activity against the class C enzymes, avibactam is a potent inhibitor of AmpC  $\beta$ -lactamases.<sup>3,5</sup> It is the first non- $\beta$ -lactam  $\beta$ -lactamase inhibitor to advance

to clinical development, currently undergoing Phase II–III clinical trials in combination with ceftazidime and with ceftaroline (<http://www.clinicaltrials.gov>). Ceftaroline, like some third-generation cephalosporins, is a weak inducer of AmpC enzymes at sub-MIC concentrations, resulting in a propensity to select AmpC-derepressed or AmpC-hyperinducible mutants.<sup>19</sup> Pairing ceftaroline with avibactam should thus be an effective strategy to limit the risk of selection of mutants, and to restore ceftaroline activity against AmpC-hyperproducing strains, as well as to other  $\beta$ -lactamase producers.

## Acknowledgment

The authors are very grateful to Dr Ken Coleman for critical review of the manuscript.

## Disclosure

This work was presented in abstract form at the International Congress of Antimicrobial Agents and Chemotherapy in 2006. The authors report no conflicts of interest in this work.

## References

- Poole K. Resistance to  $\beta$ -lactam antibiotics. *Cell Mol Life Sci*. 2004;61:2200–2223.
- Drawz SM, Bonomo R. Three decades of  $\beta$ -lactamase inhibitors. *Clin Microbiol Rev*. 2010;23:160–201.
- Stachyra T, P echereau MC, Bruneau JM, et al. Mechanistic studies of the inactivation of TEM-1 and P99 by NXL104, a novel non- $\beta$ -lactam  $\beta$ -lactamase inhibitor. *Antimicrob Agents Chemother*. 2010;54:5132–5138.
- Ehmann DE, Jahi c H, Ross PL, et al. Avibactam is a covalent, reversible, non- $\beta$ -lactam  $\beta$ -lactamase inhibitor. *Proc Natl Acad Sci U S A*. 2012;109:11663–11668.
- Bonnefoy A, Dupuis-Hamelin C, Steier V, et al. In vitro activity of AVE1330A, an innovative broad-spectrum non- $\beta$ -lactam  $\beta$ -lactamase inhibitor. *J Antimicrob Chemother*. 2004;54:410–417.
- Livermore DM, Mushtaq S, Warner M, Miossec C, Woodford N. NXL104 combinations versus Enterobacteriaceae with CTX-M extended-spectrum  $\beta$ -lactamases and carbapenemases. *J Antimicrob Chemother*. 2008;62:1053–1056.
- Stachyra T, Levasseur P, P echereau MC, et al. In vitro activity of the  $\beta$ -lactamase inhibitor NXL104 against KPC-2 carbapenemase and Enterobacteriaceae expressing KPC carbapenemases. *J Antimicrob Chemother*. 2009;64:326–329.
- Jones RN. Important and emerging  $\beta$ -lactamase-mediated resistances in hospital-based pathogens: the AmpC enzymes. *Diagn Microbiol Infect Dis*. 1998;31:461–466.
- Jacoby GA. AmpC  $\beta$ -lactamases. *Clin Microbiol Rev*. 2009;22:161–182.
- Kitzis MD, Ferr e B, Coutrot A, et al. In vitro activity of combinations of  $\beta$ -lactam antibiotics with  $\beta$ -lactamase inhibitors against cephalosporinase-producing bacteria. *Eur J Clin Microbiol Infect Dis*. 1989;8:783–788.
- Lister PD, Gardner VM, Sanders CC. Clavulanate induces expression of the *Pseudomonas aeruginosa* AmpC cephalosporinase at physiologically relevant concentrations and antagonizes the antibacterial activity of ticarcillin. *Antimicrob Agents Chemother*. 1999;43:882–889.
- Sanders CC, Sanders WE Jr, Goering RV. In vitro antagonism of  $\beta$ -lactam antibiotics by ceftoxitin. *Antimicrob Agents Chemother*. 1982;21:968–975.
- Clinical and Laboratory Standards Institute. *Performance Standards for Antimicrobial Susceptibility Testing: Eighteenth International Supplement*. Wayne (PA): CLSI; 2010.
- Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the  $2^{-\Delta\Delta C_T}$  method. *Methods*. 2001;25:402–408.
- Livermore DM, Winstanley TG, Shannon KP. Interpretative reading: recognizing the usual and inferring resistance mechanisms from resistance phenotypes. *J Antimicrob Chemother*. 2001;48 Suppl 1:87–102.
- Dunne WM Jr, Hardin DJ. Use of several inducer and substrate antibiotic combinations in a disk approximation assay format to screen for AmpC induction in patients isolates from *Pseudomonas aeruginosa*, *Enterobacter* spp., *Citrobacter* spp., and *Serratia* spp. *J Clin Microbiol*. 2005;43:5945–5949.
- Pfaller MA, Jones RN. Antimicrobial susceptibility of inducible AmpC  $\beta$ -lactamase-producing Enterobacteriaceae from the Mero-penem Yearly Susceptibility Test Information Collection (MYSTIC) Programme, Europe 1997–2000. *Int J Antimicrob Agents*. 2002;19:383–388.
- Kong KF, Aguila A, Schnepfer L, Mathee K. *Pseudomonas aeruginosa*  $\beta$ -lactamase induction requires two permeases, AmpG and AmpP. *BMC Microbiol*. 2010;10:328.
- Mushtaq S, Livermore DM. AmpC induction by ceftaroline. *J Antimicrob Chemother*. 2010;65:266–270.

### Infection and Drug Resistance

## Publish your work in this journal

Infection and Drug Resistance is an international, peer-reviewed open-access journal that focuses on the optimal treatment of infection (bacterial, fungal and viral) and the development and institution of preventive strategies to minimize the development and spread of resistance. The journal is specifically concerned with the epidemiology of antibiotic

Submit your manuscript here: <http://www.dovepress.com/infection-and-drug-resistance-journal>

resistance and the mechanisms of resistance development and diffusion in both hospitals and the community. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Dovepress